OTC Plan B in Canada?
This article was originally published in The Tan Sheet
Executive SummaryCanada's National Drug Scheduling Advisory Committee recommends Paladin Labs' application to move emergency contraceptive Plan B from behind-the-counter to full over-the-counter status, Paladin announces April 14. A 30-day comment period will follow NDSAC's recommendation to the National Association of Pharmacy Regulatory Authorities, an independent body that works with Health Canada, Paladin explains. NAPRA will decide whether to endorse the NDSAC recommendation after the comment period closes. "While there is no guarantee of NAPRA's decision, it usually follows NDSAC's recommendations," Paladin states. If NAPRA endorses the recommendation, pharmacies could sell Plan B OTC beginning "around mid-May," the firm says. Unlike the U.S., Canada does not have an 18-and-older requirement for behind-the-counter Plan B and would allow open access to the emergency contraceptive if the product goes OTC, the Montreal-based specialty pharmaceuticals firm explains. The firm acquired the exclusive Canadian distribution rights to Duramed's Plan B in December 1999...
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.
Strides has set a sales target of $200-400m for Stelis’s generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’s Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.